Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant 90Y-DOTATOC in Pancreatic Neuroendocrine Tumours
NCT05568017Phase 2Terminated
- Sponsor
- European Institute of Oncology
- Start
- Sep 2020
- Primary completion
- Sep 2022
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of yttrium-90 edotreotide in Pancreatic neuroendocrine tumor (PanNET), sponsored by European Institute of Oncology. Started Sep 2020; status: terminated.
02
Drugs
yttrium-90 edotreotide
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT05568017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05568017.